Venetoclax as Salvage Treatment for Relapsed/Refractory B-ALL Post-CAR-T Therapy.
BACKGROUND Despite high early response rates following chimeric antigen receptor T-cell therapy (CAR-T) for relapsed/refractory pediatric B-cell acute lymphoblastic leukemia (B-ALL), many patients relapse, and downregulation of the antigen targeted by the CAR-T has emerged as a major challenge. Furthermore, minimal res...